Infectious Disease
Q&A: BARDA wants to back tech that can combat multiple infections, says director
Following the rapid development and commercialisation of Covid-19 vaccines and therapeutics, multiple pharmaceutical companies such as AstraZeneca, Moderna, and Pfizer…
Johnson & Johnson’s paediatric HIV-1 treatment secures FDA approval
Johnson & Johnson has received approval from the US Food and Drug Administration (FDA) approval for EDURANT PED to treat…
Merck to start trials investigating single dosing regimen of HPV vaccine
Merck & Co (MSD) plans to start two prospective clinical trials evaluating the safety and efficacy of a single-dose regimen…
Anticipation rises for RSV rollout as positive data emerges
After record-high levels of respiratory syncytial virus (RSV) were seen in several countries, the pharmaceutical landscape for RSV infections has…
Bavarian Nordic’s chikungunya vaccine secures EMA fast-track
Hot on the heels of dropping its cancer vaccine programme, Bavarian Nordic has secured a win in more familiar territory,…
AstraZeneca completes Icosavax acquisition for $1.1bn
AstraZeneca has concluded the acquisition of the US-based clinical-stage biopharmaceutical company Icosavax in a $1.1bn deal. The latest development comes…
FDA grants fast track status to GSK’s bepirovirsen for hepatitis B
The US Food and Drug Administration (FDA) has granted fast track designation to GSK’s bepirovirsen, an investigational treatment for chronic…
Emergent wins $235.8m US defence contract for Anthrax vaccine
The US Department of Defense (DoD) has awarded a procurement contract worth up to $235.8m to Emergent BioSolutions for an…
Curevo looks to challenge GSK’s Shingrix with positive Phase II data
Curevo Vaccine’s varicella-zoster virus vaccine amezosvatein has achieved all primary endpoints, including demonstrating non-inferiority to GSK’s Shingrix in a Phase…
FDA accepts Merck’s pneumococcal vaccine BLA for priority review
The US Food and Drug Administration (FDA) has accepted the new biologics licence application (BLA) for MSD’s investigational 21-valent pneumococcal…
